| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A Model to Predict Future Biologic or Targeted Synthetic DMARD Switch at a Subsequent Clinic Visit in Rheumatoid Arthritis
|
Cappelli, Laura C.
|
|
|
10 |
6 |
p. 1669-1681
|
artikel
|
| 2 |
Analysis of Factors Influencing Whole Blood Hydroxychloroquine Concentration in Patients with Systemic Lupus Erythematosus in China
|
Huang, Xuan
|
|
|
10 |
6 |
p. 1597-1607
|
artikel
|
| 3 |
A Real-World Effectiveness Study Using a Mobile Application to Evaluate Early Outcomes with Upadacitinib in Rheumatoid Arthritis
|
Harrold, Leslie R.
|
|
|
10 |
6 |
p. 1519-1533
|
artikel
|
| 4 |
Association Between Mycophenolate Mofetil Use and Subsequent Infections Among Hospitalized Patients with Systemic Lupus Erythematosus: A Nested Case–Control Study
|
Guo, Qingqing
|
|
|
10 |
6 |
p. 1535-1554
|
artikel
|
| 5 |
Clinical Outcomes in Patients with Rheumatoid Arthritis After Switching Between Interleukin-6-Receptor Inhibitors and Janus Kinase Inhibitors: Findings from an Observational Study
|
Dua, Anisha B.
|
|
|
10 |
6 |
p. 1753-1768
|
artikel
|
| 6 |
Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European Patients
|
Alten, Rieke
|
|
|
10 |
6 |
p. 1575-1595
|
artikel
|
| 7 |
Correction: Effectiveness of Etanercept in Rheumatoid Arthritis: Real-World Data from the German Non-interventional Study ADEQUATE with Focus on Treat-to-Target and Patient-Reported Outcomes
|
Feist, Eugen
|
|
|
10 |
6 |
p. 1809-1810
|
artikel
|
| 8 |
Effect of Filgotinib on Body Mass Index (BMI) and Effect of Baseline BMI on the Efficacy and Safety of Filgotinib in Rheumatoid Arthritis
|
Balsa, Alejandro
|
|
|
10 |
6 |
p. 1555-1574
|
artikel
|
| 9 |
Efficacy and Safety of Inebilizumab in IgG4-Related Disease: Protocol for a Randomized Controlled Trial
|
Perugino, Cory
|
|
|
10 |
6 |
p. 1795-1808
|
artikel
|
| 10 |
Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study
|
Mease, Philip J.
|
|
|
10 |
6 |
p. 1637-1653
|
artikel
|
| 11 |
Generation-Dependent Retention Rates and Reasons for Discontinuation of Molecular Targeted Therapies in Patients with Rheumatoid Arthritis: From FIRST Registry
|
Kubo, Satoshi
|
|
|
10 |
6 |
p. 1705-1723
|
artikel
|
| 12 |
Identification of the Minimal Disease Activity Domains Achieved Based on Different Treatments in Psoriatic Arthritis
|
Scriffignano, Silvia
|
|
|
10 |
6 |
p. 1785-1794
|
artikel
|
| 13 |
Ixekizumab Efficacy in Patients with Severe Peripheral Psoriatic Arthritis: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (SPIRIT-P1)
|
Kameda, Hideto
|
|
|
10 |
6 |
p. 1683-1703
|
artikel
|
| 14 |
Pregnancy Outcomes in Patients with Primary Sjögren’s Syndrome Undergoing Assisted Reproductive Therapy: A Multi-center Retrospective Study
|
Lao, Minxi
|
|
|
10 |
6 |
p. 1725-1739
|
artikel
|
| 15 |
Prevention of Radiographic Progression in Higher-Risk Patients with Rheumatoid Arthritis Using Filgotinib in Phase III Studies: Narrative Review of Post Hoc Analyses
|
Tanaka, Yoshiya
|
|
|
10 |
6 |
p. 1399-1415
|
artikel
|
| 16 |
Psoriasis and Psoriatic Arthritis Have a Major Impact on Quality of Life and Depressive Symptoms: A Cross-Sectional Study of 300 Patients
|
Frede, Natalie
|
|
|
10 |
6 |
p. 1655-1668
|
artikel
|
| 17 |
Risk of Macrophage Activation Syndrome in Patients with Adult-Onset Still’s Disease Treated with IL-1 and IL-6 Inhibitors: A Meta-analysis and Single-Center Experience
|
Adachi, Soichiro
|
|
|
10 |
6 |
p. 1623-1636
|
artikel
|
| 18 |
Safety and Effectiveness of Baricitinib in Chinese Patients with Moderate-to-Severe Rheumatoid Arthritis: 24-Week Results from a Post-Marketing Safety Study
|
Wu, Chan-yuan
|
|
|
10 |
6 |
p. 1609-1622
|
artikel
|
| 19 |
Safety, Tolerability, and Pharmacokinetics of Same-Knee Intra-Articular Injection of Corticosteroid and Lorecivivint Within 7 Days: An Open-Label, Randomized, Parallel-Arm Study
|
Fineman, Mark S.
|
|
|
10 |
6 |
p. 1741-1752
|
artikel
|
| 20 |
Serum Calprotectin as a Potential Predictor of Microvascular Manifestations in Patients with Antiphospholipid Syndrome
|
Zhao, Yuan
|
|
|
10 |
6 |
p. 1769-1783
|
artikel
|
| 21 |
Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
|
Mease, Philip J.
|
|
|
10 |
6 |
p. 1479-1501
|
artikel
|
| 22 |
Systematic Literature Review of Real-World Evidence on Baricitinib for the Treatment of Rheumatoid Arthritis
|
Hernández-Cruz, Blanca
|
|
|
10 |
6 |
p. 1417-1457
|
artikel
|
| 23 |
Targeting DORIS Remission and LLDAS in SLE: A Review
|
Parra Sánchez, Agner R.
|
|
|
10 |
6 |
p. 1459-1477
|
artikel
|
| 24 |
Treatment with Upadacitinib in Active Psoriatic Arthritis: Efficacy and Safety Data of the First 192 Patients from the UPJOINT Study, a Multicentre, Observational Study in Clinical Practice
|
Werner, Stephanie G.
|
|
|
10 |
6 |
p. 1503-1518
|
artikel
|
Tijdschrift beschrijving